

# Table of Contents

<b>1</b>	<b>Introduction .....</b>	<b>1</b>
1.1	The immune system .....	1
1.2	The concept of immune surveillance theory .....	1
1.3	Immune surveillance of human cancer .....	4
1.4	Presentation of tumor antigens to T cells.....	5
1.5	Tumor antigens.....	7
1.6	Relevance of existing cancer models to study tumor-specific T cell responses and immune surveillance.....	8
1.7	Tumorigenesis by SV40 large T and its application in animal models.....	11
1.8	Gene regulation by the Tet system.....	13
1.9	Non-invasive bioluminescent imaging.....	15
<b>2</b>	<b>Aims .....</b>	<b>17</b>
<b>3</b>	<b>Results .....</b>	<b>19</b>
3.1	Selection and characterization of transplantable cancer cell lines allowing <i>in</i> <i>vivo</i> studies of T cell responses against a neoantigen .....	19
3.1.1	Establishment of cancer cell lines with conditional oncogene/antigen expression .....	19
3.1.2	Conditional oncogene inactivation resulted in decreased TagLuc expression and proliferative arrest of cancer cells.....	21
3.1.3	Cancer cells were not recognized by Tag-specific CD8 <sup>+</sup> T cells <i>in vitro</i> upon oncogene/antigen inactivation .....	26
3.2	Induction of Tag-specific CD8 <sup>+</sup> T cell responses upon <i>de novo</i> TagLuc expression in the absence of acute inflammation.....	27
3.2.1	Cancer cells survived in immunodeficient mice upon oncogene inactivation and tumors grew out after re-induced TagLuc expression ....	28
3.2.2	TagLuc expression by resting cancer cells resulted in rapid BL signal induction followed by loss of BL signal in immunocompetent hosts .....	31
3.2.3	BL signal loss in immunocompetent mice was accompanied by induction of Tag-specific CD8 <sup>+</sup> T cells .....	33
3.2.4	TagLuc was induced <i>in vivo</i> only in a fraction of originally inoculated cancer cells.....	35
3.2.5	TagLuc induction in a low number of cancer cells resulted in rejection and induction of Tag-specific CD8 <sup>+</sup> T cells .....	38
3.2.6	Inoculation of TagLuc-inactivated cancer cells did not induce an unintended Tag-specific CD8 <sup>+</sup> T cell response in CM2 mice .....	39

3.2.7 Old mice still rejected TagLuc <sup>+</sup> clone 4 cancer cells and developed a Tag-specific CD8 <sup>+</sup> T cell response .....	42
3.2.8 Low TagLuc expression on clone 3D3 cancer cells induced Tag-specific CD8 <sup>+</sup> T cells and resulted in regression of cancer cells .....	46
3.3 Direct priming as a potential mechanism for induction of Tag-specific CD8 <sup>+</sup> T cells in the absence of acute inflammation.....	50
3.3.1 Naïve TCR-I T cells were primed directly <i>in vitro</i> by TagLuc <sup>+</sup> cancer cells.....	50
3.3.2 TCR-I T cells rejected TagLuc <sup>+</sup> cancer cells in the absence of antigen cross-presentation by host cells .....	54
3.3.3 Naïve Tag-specific CD8 <sup>+</sup> T cells expanded and rejected TagLuc <sup>+</sup> cancer cells in the absence of CD4 <sup>+</sup> T cell help .....	57
<b>4 Discussion.....</b>	<b>63</b>
4.1 A cancer transplantation model for studies of <i>de novo</i> T cell responses against neoantigens expressed in the absence of acute inflammation.....	63
4.1.1 Requirements of an appropriate cancer transplantation model.....	63
4.1.2 Suitability of cancer cells expressing Tet system-regulated TagLuc .....	64
4.1.3 Advantages of cancer cell visualization by BL imaging .....	64
4.1.4 Lack of recognition of cancer cells ‘off dox’ by CD8 <sup>+</sup> T cells .....	65
4.1.5 Convergence of the model to human sporadic cancer .....	66
4.1.6 Limitations and prospects of the model.....	66
4.2 Immune response to newly expressed TagLuc on cancer cells in the absence of acute inflammation .....	68
4.2.1 Spontaneous CD8 <sup>+</sup> T cell responses against TagLuc expressed on cancer cells under resting conditions.....	68
4.2.2 Immune response to TagLuc in old mice .....	71
4.2.3 Immune response to cancer cells expressing low levels of TagLuc .....	71
4.3 Direct priming of Tag-specific CD8 <sup>+</sup> T cells.....	72
4.3.1 Co-stimulatory molecules.....	72
4.3.2 Direct priming in tumor-draining lymph nodes.....	73
4.3.3 Role of CD4 <sup>+</sup> T cells in priming of Tag-specific CD8 <sup>+</sup> T cells.....	73
4.3.4 Role of cross-presentation in priming of Tag-specific CD8 <sup>+</sup> T cells .....	74
4.4 Concluding remarks .....	76
<b>5 Material and Methods .....</b>	<b>79</b>
5.1 Material .....	79
5.1.1 Kits.....	79
5.1.2 Cell culture media.....	79
5.1.3 Mouse strains .....	79

5.1.4 Cell lines .....	81
5.1.5 Adenovirus.....	81
5.1.6 Oligonucleotides for PCR.....	82
5.1.7 Antibodies and tetramers .....	82
5.2 Methods.....	84
5.2.1 Selection of cancer cell lines with conditional TagLuc expression.....	84
5.2.2 Cancer cell transplantation .....	84
5.2.3 Doxycycline treatment.....	84
5.2.4 Luciferase activity assay.....	85
5.2.5 <i>In vitro</i> T cell antigen recognition assay.....	85
5.2.6 <i>In vivo</i> T cell proliferation assay .....	85
5.2.7 Flow cytometry .....	85
5.2.8 Bioluminescent imaging .....	86
5.2.9 Immunoblotting .....	86
5.2.10 BrdU incorporation assay .....	86
5.2.11 INF- $\gamma$ ELISA .....	87
5.2.12 DNA amplification and detection of recombination .....	87
5.2.13 <i>In vitro</i> direct priming assay.....	88
5.2.14 <i>In vivo</i> direct priming assay.....	89
5.2.15 CD4 $^{+}$ T cell depletion experiment.....	89
5.3 Suppliers.....	90
<b>6 Bibliography .....</b>	<b>91</b>
<b>7 Abbreviations.....</b>	<b>107</b>
<b>8 Acknowledgement .....</b>	<b>111</b>
<b>9 Appendix .....</b>	<b>113</b>